CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Clostridium botulinum neurotoxin type A, free from complexing proteins

Last Updated: June 12, 2009
Result type: Reports
Project Number: S0192
Product Line: Reimbursement Review

Generic Name: Clostridium botulinum neurotoxin type A, free from complexing proteins

Brand Name: Xeomin

Manufacturer: Merz Pharmaceuticals GmbH

Indications: Cervical Dystonia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 16, 2009

Recommendation Type: List in a similar manner